Table 1.
Characteristics of study subjects
| AF patients, N=50 | Controls, N=11 | P-value | |
|---|---|---|---|
| Male | 37 (74%) | 10 (77%) | 0.83 |
| Age, years | 60 ± 8 | 57 ± 8 | 0.080 |
| BMI, kg/m2 | 27.9 ± 4.0 | 24.4 ± 3.0 | 0.009 |
| SBP, mmHg | 120 ± 15 | 108 ± 33 | 0.057 |
| DBP, mmHg | 75 ± 13 | 75 ± 14 | 0.84 |
| HR, beats per minutes | 63 ± 10 | 63 ± 9 | 0.70 |
| CAD risk factors | |||
| Hypertension | 14 (28%) | 0 (0%) | 0.046 |
| Dyslipidemia | 16 (32%) | 0 (0%) | 0.028 |
| Diabetes mellitus | 3 (6%) | 0 (0%) | 0.40 |
| Current smoker | 1 (2%) | 0 (0%) | 0.64 |
| Family history of CAD | 9 (18%) | 1 (8%) | 0.47 |
| Medication | |||
| Calcium channel blocker | 9 (18%) | 0 (0%) | 0.13 |
| ACE/ARB | 9 (18%) | 0 (0%) | 0.13 |
| Beta blocker | 23 (46%) | 0 (0%) | 0.004 |
| Anti-arrhythmic agent | 23 (46%) | 0 (0%) | 0.004 |
| Anticoagulant | 41 (82%) | 0 (0%) | < 0.001 |
| Statin | 18 (36%) | 0 (0%) | 0.017 |
| CHA2DS2-VASc score | 1.0 ± 1.1 | 0.1 ± 0.3 | 0.011 |
| Duration of AF, years | 3.9 ± 4.9 | - | - |
ACE; angiotensin converting enzyme inhibitors, AF; atrial fibrillation, ARB; angiotensin receptor blockers, BMI; body mass index, CAD; coronary artery disease, DBP; diastolic blood pressure, HR; heart rate, SBP; systolic blood pressure